From the 56th Annual Scientific Session of the American College of Cardiology: EVEREST: Tolvaptan improves symptoms, volume status in patients with acute decompensated HF but offers no long-term impact


The investigational vasopressin receptor antagonist tolvaptan had no long-term impact on clinical events in patients hospitalized with acute decompensated heart failure (ADHF), but the agent did improve symptoms and volume status over the short term, according to results presented at the 56th annual ACC scientific session.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.